BACKGROUND & AIMS: Symplekin is a ubiquitously expressed protein involved in RNA polyadenylation and transcriptional regulation that localizes at tight junctions in epithelial cells. The association between symplekin and the Y-box transcription factor ZONAB activates proliferation in intestinal and kidney cells. We analyzed symplekin expression in human colonic crypts and investigated its function in differentiation. METHODS: Expression of differentiation markers and transcription factors was assessed in HT29-Cl.16E cells that expressed inducible symplekin short hairpin RNA or were transfected with ZONAB small interfering RNAs. Intestines of AML1(Delta/Delta) mice were stained with alcian blue and analyzed for expression of AML1/Runx1, GAPDH, KLF-4, and Muc-2. Mobility shift and chromatin immunoprecipitation were used to detect AML1 and ZONAB/DbpA binding to promoter regions of the Krüppel-like factor 4 (KLF4) and acute myeloid leukemia-1 (AML1) genes, respectively. RESULTS: The gradient of nuclear symplekin expression decreased from the proliferative toward the differentiated compartment of colonic crypts; symplekin down-regulation promoted the differentiation of HT29-Cl.16E colorectal carcinoma cells into goblet cells. Down-regulation of symplekin or ZONAB/Dbpa induced de novo expression of the transcription factor AML1/Runx1, thereby increasing the expression of KLF4 and promoting goblet cell differentiation. Furthermore, increased AML1 expression was required for the induction of goblet cell differentiation after symplekin down-regulation. KLF4 expression and goblet cell numbers were reduced in the intestines of AML1(Delta/Delta) mice, confirming the role of AML1 as a promoter of intestinal differentiation in vivo. CONCLUSIONS: Symplekin cooperates with ZONAB to negatively regulate intestinal goblet cell differentiation, acting by repression of AML1 and KLF4.
BACKGROUND & AIMS: Symplekin is a ubiquitously expressed protein involved in RNA polyadenylation and transcriptional regulation that localizes at tight junctions in epithelial cells. The association between symplekin and the Y-box transcription factor ZONAB activates proliferation in intestinal and kidney cells. We analyzed symplekin expression in human colonic crypts and investigated its function in differentiation. METHODS: Expression of differentiation markers and transcription factors was assessed in HT29-Cl.16E cells that expressed inducible symplekin short hairpin RNA or were transfected with ZONAB small interfering RNAs. Intestines of AML1(Delta/Delta) mice were stained with alcian blue and analyzed for expression of AML1/Runx1, GAPDH, KLF-4, and Muc-2. Mobility shift and chromatin immunoprecipitation were used to detect AML1 and ZONAB/DbpA binding to promoter regions of the Krüppel-like factor 4 (KLF4) and acute myeloid leukemia-1 (AML1) genes, respectively. RESULTS: The gradient of nuclear symplekin expression decreased from the proliferative toward the differentiated compartment of colonic crypts; symplekin down-regulation promoted the differentiation of HT29-Cl.16E colorectal carcinoma cells into goblet cells. Down-regulation of symplekin or ZONAB/Dbpa induced de novo expression of the transcription factor AML1/Runx1, thereby increasing the expression of KLF4 and promoting goblet cell differentiation. Furthermore, increased AML1 expression was required for the induction of goblet cell differentiation after symplekin down-regulation. KLF4 expression and goblet cell numbers were reduced in the intestines of AML1(Delta/Delta) mice, confirming the role of AML1 as a promoter of intestinal differentiation in vivo. CONCLUSIONS: Symplekin cooperates with ZONAB to negatively regulate intestinal goblet cell differentiation, acting by repression of AML1 and KLF4.
Authors: H C Bauer; A Traweger; J Zweimueller-Mayer; C Lehner; H Tempfer; I Krizbai; I Wilhelm; H Bauer Journal: J Neural Transm (Vienna) Date: 2010-09-24 Impact factor: 3.575
Authors: Cheng Zhu; Eva Sauter; Anja Schreiter; Claudia R C van Roeyen; Tammo Ostendorf; Jürgen Floege; Florian Gembardt; Christian P Hugo; Berend Isermann; Jonathan A Lindquist; Peter R Mertens Journal: J Am Soc Nephrol Date: 2016-05-05 Impact factor: 10.121
Authors: Hansong Wang; Stephanie L Schmit; Christopher A Haiman; Temitope O Keku; Ikuko Kato; Julie R Palmer; David van den Berg; Lynne R Wilkens; Terrilea Burnett; David V Conti; Fredrick R Schumacher; Lisa B Signorello; William J Blot; Krista A Zanetti; Curtis Harris; Mala Pande; Sonja I Berndt; Polly A Newcomb; Dee W West; Robert Haile; Daniel O Stram; Jane C Figueiredo; Loïc Le Marchand Journal: Int J Cancer Date: 2017-03-28 Impact factor: 7.396
Authors: Remond J A Fijneman; Rebecca A Anderson; Ethan Richards; Jieming Liu; Marianne Tijssen; Gerrit A Meijer; Janae Anderson; Annette Rod; Michael G O'Sullivan; Patricia M Scott; Robert T Cormier Journal: Cancer Sci Date: 2012-01-19 Impact factor: 6.716
Authors: Anastasios Georgiadis; Marion Tschernutter; James W B Bainbridge; Kamaljit S Balaggan; Freya Mowat; Emma L West; Peter M G Munro; Adrian J Thrasher; Karl Matter; Maria S Balda; Robin R Ali Journal: PLoS One Date: 2010-12-30 Impact factor: 3.240